Coverage for weight loss medications, including those used to treat associated comorbidities, will be excluded from the following commercial product segments: Tufts Health Direct Products (MA) Harvard Pilgrim Individual & Small Group Products (NH, RI) Harvard Pilgrim Merged Market Products (MA, ME) Harvard Pilgrim Large Group Products (MA, NH, ME, RI) on the Select formulary (starting on group anniversary dates) This decision reflects in response to evolving FDA approvals and the broader use of these medications for alternative indications such as cardiovascular conditions
In addition to GLP-1 RA medications
843-857, Sep
Trimi's published homepage displays a figure of 53,585+ patients, which should be treated as brand-stated information - it hasn't been independently audited by this publication
Until May 2025, every "tirzepatide vs semaglutide" comparison was cross-trial, meaning the two compounds had never been tested in the same study population
Direct Receptor-Mediated Effects : While preclinical studies suggest GLP-1 receptors may be present in bone tissue, the clinical relevance of direct receptor activation in human bone cells remains uncertain and controversial
